Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

Open access
Taylor, Graham S., Jia, Hui, Harrington, Kevin, Lee, Lip Wai, Turner, James, Ladell, Kristin, Price, David A., Tanday, Manjit, Matthews, Jen, Roberts, Claudia, Edwards, Ceri, McGuigan, Lesley, Hartley, Andrew, Wilson, Steve, Hui, Edwin P., Chan, Anthony T. C., Rickinson, Alan B., Steven, Neil M. · 2014 · Clinical Cancer Research

Abstract

Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor antigens. A phase I trial was conducted to demonstrate the safety and immunogenicity of MVA-EL across a range of doses. Experimental Design: Sixteen patients in the United Kingdom (UK) with EBV-positive nasopharyngeal carcinoma (NPC) received three intradermal vaccinations of MVA-EL at 3-weekly intervals at dose levels between 5 × 107 and 5 × 108 plaque-forming units (pfu). Blood samples were taken at screening, after each vaccine cycle, and during the post-vaccination period. T-cell responses were measured using IFNγ ELISpot assays with overlapping EBNA1/LMP2 peptide mixes or HLA-matched epitope peptides. Polychromatic flow cytometry was used to characterize functionally responsive T-cell populations. Results: Vaccination was generally well tolerated. Immunity increased after vaccination to at least one antigen in 8 of 14 patients (7/14, EBNA1; 6/14, LMP2), including recognition of epitopes that vary between EBV strains associated with different ethnic groups. Immunophenotypic analysis revealed that vaccination induced differentiation and functional diversification of responsive T-cell populations specific for EBNA1 and LMP2 within the CD4 and CD8 compartments, respectively. Conclusions: MVA-EL is safe and immunogenic across diverse ethnicities and thus suitable for use in trials against different EBV-positive cancers globally as well as in South-East Asia where NPC is most common. The highest dose (5 × 108 pfu) is recommended for investigation in current phase IB and II trials. Clin Cancer Res; 20(19); 5009–22. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1122-t

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 189

Metadata

Authors
Taylor, G. S., Jia, H., Harrington, K., Lee, L. W., Turner, J., Ladell, K., Price, D. A., Tanday, M., Matthews, J., Roberts, C., Edwards, C., McGuigan, L., Hartley, A., Wilson, S., Hui, E. P., Chan, A. T. C., Rickinson, A. B., & Steven, N. M.
Venue
Clinical Cancer Research
Published
2014-09-30
Volume
20
Issue
19
Pages
5009-5022
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1968120911
Cited by
189
References
2
FWCI
4.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1122-t
The paper
Taylor, G. S., Jia, H., Harrington, K., Lee, L. W., Turner, J., Ladell, K., Price, D. A., Tanday, M., Matthews, J., Roberts, C., Edwards, C., McGuigan, L., Hartley, A., Wilson, S., Hui, E. P., Chan, A. T. C., Rickinson, A. B., & Steven, N. M. (2014). A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1122-t

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.